Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated...
Radioactive Iodine-refractory Differentiated Thyroid CancerThis is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition...
Metastatic Thyroid CancerThis is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients...
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck Carcinoma61 moreThis phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
Thyroid-Associated OphthalmopathyThe purpose of this study is to determine whether Sirolimus is more effective and burdened with less side effects than conventional treatment with corticosteroids in patients with active thyroid eye disease.
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
Thyroid Eye DiseaseThe investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid Eye Disease.
A Study to Evaluate the Safety and Pharmacokinetic Properties of LASN01 in Healthy Subjects and...
Pulmonary FibrosisThyroid Eye DiseaseLASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for fibrosis. This study is a four-part trial consisting of Parts A, B, C and D. The primary objective of this study is to evaluate the safety, tolerability, and the secondary objective is to evaluate the immunogenicity and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED).
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer...
Thyroid CancerThis research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. - The name of the study intervention involved in this study is regorafenib.
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer...
BRAF NP_004324.2:p.V600EBRAF V600K Mutation Present1 moreThis trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
Metastatic Differentiated Thyroid CancerFailure of conventional radioiodine therapy of metastatic differentiated thyroid cancer could be explained by: a suboptimal therapeutic approach, based on the administration of empirically fixed amount of radioactivity the presence of lesions with impaired iodine uptake, due to the expression of specific mutations The study aims to: optimize therapy with pre-treatment 124-I blood and lesion dosimetry collect genetic data to check if specific mutations and/or miRNA over-expression could be related to low iodine uptake or to radioresistance
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease...
Thyroid Eye DiseaseGraves Orbitopathy10 moreThe overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).